Brief: Enanta Pharmaceuticals Initiates A Phase 2B Clinical Study Of EDP-938
03/10/2022 12:16
Oct 3 (Reuters) - Enanta Pharmaceuticals Inc ENTA.O :
* ENANTA PHARMACEUTICALS INITIATES A PHASE 2B CLINICAL STUDY
OF
EDP-938 IN HIGH-RISK ADULTS WITH RESPIRATORY SYNCYTIAL VIRUS
Source text for Eikon: ID:nBw8l5CCKa
Further company coverage: ENTA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Enanta Pharmaceuticals
See all newsEnanta Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Enanta Pharmaceuticals Q3 revenue misses estimates, hurt by lower royalties
Enanta Pharmaceuticals Inc expected to post a loss of 51 cents a share - Earnings Preview
Enanta Pharma Q2 loss narrows on higher AbbVie royalties, lower costs
Enanta Pharmaceuticals Q1 revenue beats estimates